#aaeth ,,congress  #b;d ,session  ,h4   
,r4 #eehb  ,,an ,,act  ,to direct the   
,secretary of ,health and ,human        
,services to conduct a study and submit 
a report on barriers to accessing       
abuse-deterrent opioid formulations for 
individuals enrolled in a plan under    
part ,c or ,d of the ,medicare program4 
#a4 ,short title ,this ,act may be cited
 at the ,abuse ,deterrent ,access ,act  
of #bjah4  #b4 ,study on abuse-deterrent
 opioid formulations access barriers    
under ,medicare  7a7 ,in general ,not   
later than on#a;e year after the date of
 the enactment of this ,act1 the        
,secretary of ,health and ,human        
,services shall conduct a study and     
submit to ,congress a report on the     
adequacy of access to abuse-deterrent   
opioid formulations for individuals with
 chronic pain enrolled in an ,,ma-,,pd  
plan under part ,c of title ,,xviii of  
the ,social ,security ,act or a         
prescription drug plan under part ,d of 
such title of such ,act1 taking into    

account any barriers preventing such    
individuals from accessing such         
formulations under such ,,ma-,,pd or    
part ,d plans1 such as cost-sharing     
tiers1 fail-first requirements1 the     
price of such formulations1 and prior   
authorization requirements4  7b7        
,definition of abuse-,deterrent opioid  
formulation ,in this section1 the term  
abuse-deterrent opioid formulation means
 an opioid that is a prodrug or that has
 certain abuse-deterrent properties1    
such as physical or chemical barriers1  
agonist or antagonist combinations1     
aversion properties1 delivery system    
mechanisms1 or other features designed  
to prevent abuse of such opioid4        
,passed the ,house of ,representatives  
,june #ab1 #bjah4;,clerk4